Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysis

Objective This study aimed to determine the number needed to treat (NNT), number needed to harm (NNH), and likelihood of being helped or harmed (LHH) in a post hoc analysis of the phase 3b FOCUS trial. Background Fremanezumab, a humanized monoclonal antibody that selectively targets calcitonin gene–...

Full description

Saved in:
Bibliographic Details
Published in:Headache 2023-11, Vol.63 (10), p.1351-1358
Main Authors: Ashina, Messoud, Mitsikostas, Dimos D., Ramirez Campos, Verena, Barash, Steve, Ning, Xiaoping, Diener, Hans‐Christoph
Format: Article
Language:English
Subjects:
Adult
Antibodies, Monoclonal
Calcitonin
Calcitonin gene-related peptide
Double-Blind Method
fremanezumab
Headache
Humans
likelihood of being helped or harmed
Migraine
Migraine Disorders - chemically induced
Migraine Disorders - drug therapy
Migraine Disorders - prevention & control
Monoclonal antibodies
number needed to harm
number needed to treat
Numbers Needed To Treat
Placebos
Propranolol
Response rates
Topiramate
Treatment Outcome
Valproic acid
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!